Full-Time

Associate Director, Learning and Capability Development

Updated on 9/16/2026

Illumina

Illumina

5,001-10,000 employees

Develops sequencing platforms and consumables

Compensation Overview

$155.6k - $233.4k/yr

+ Bonus or commission + Equity

No H1B Sponsorship

San Diego, CA, USA

Hybrid

Hybrid schedule; required in-office frequency is not specified.

Bachelor's

Category
People & HR (1)

Get referred to Illumina

See people who can refer or advise you

Requirements
  • A Bachelor's degree and a minimum of 15 years of related experience, including at least 7 years of management experience.
  • At least 8 years of experience in talent development, capability development, or learning and development within a global, matrixed organization.
  • A Bachelor's degree, preferably in Human Resources, Organizational Development, Education, Business, or a related field.
  • Demonstrated success designing and implementing enterprise learning or capability development strategies aligned with business priorities.
  • Experience building scalable learning ecosystems, performance support resources, and capability solutions using digital, blended, and artificial intelligence-enabled approaches.
  • Experience building blended learning solutions incorporating instructor-led learning, digital learning, coaching, performance support, and knowledge resources.
  • Experience managing external learning vendors, consultants, and strategic partnerships.
  • Strong understanding of adult learning principles, leadership development, capability building, and organizational change.
  • Experience leading teams and influencing cross-functional stakeholders in support of enterprise initiatives.
  • Strong consulting, communication, and project management skills, with the ability to translate business needs into effective learning solutions.
Responsibilities
  • Develop and evolve the enterprise learning and capability development strategy in alignment with business priorities, talent frameworks, workforce needs, and organizational transformation.
  • Translate leadership, talent, and workforce capability requirements into scalable learning journeys, development experiences, performance support, and enablement solutions.
  • Lead an integrated portfolio of enterprise learning and capability-building solutions, prioritizing investments based on business value, workforce need, organizational readiness, and expected impact.
  • Architect and continuously improve a modern learning ecosystem integrating instructor-led development, digital learning, coaching, experiential learning, curated content, knowledge resources, external partners, and artificial intelligence-enabled tools.
  • Lead and develop a team responsible for designing, developing, and sourcing learning and capability solutions.
  • Partner with Talent Management leadership and Human Resources Business Partners to assess capability gaps and determine approaches to build leadership capability, workforce skills, succession readiness, internal mobility, and organizational performance.
  • Establish learning architecture, design principles, quality standards, governance, and accessibility requirements for consistent, inclusive, and engaging employee experiences.
  • Build scalable resources that support learning in the flow of work, including performance support, playbooks, toolkits, manager resources, practice opportunities, and knowledge solutions.
  • Evaluate digital platforms, artificial intelligence-enabled capabilities, and emerging tools that improve personalization, accessibility, scalability, and operational efficiency.
  • Manage strategic relationships with learning vendors, coaches, consultants, content providers, and other external partners, ensuring quality, value, integration, and alignment with enterprise standards.
  • Define and monitor measures of learner experience, capability growth, behavior change, application, workforce readiness, and business impact, using insights to continuously improve the learning portfolio.
  • Champion a culture of continuous learning by embedding development into everyday work and equipping leaders to support, reinforce, and model ongoing capability building.
  • Lead cross-functional learning and capability initiatives, influence senior stakeholders, and guide the organization through changes in how employees develop and apply new skills.
Desired Qualifications
  • Experience supporting enterprise transformation, digital transformation, or organizational change initiatives.
  • Strong artificial intelligence fluency and familiarity with Microsoft Copilot or other artificial intelligence-enabled workplace tools and their application to employee learning and productivity.
  • Experience with enterprise learning technologies such as Workday Learning, LinkedIn Learning, and similar platforms.
  • Experience developing knowledge management resources or employee enablement content.
  • An advanced degree or professional certification in Organizational Development, Learning and Development, Human Resources, Business, or a related discipline.

Illumina provides integrated sequencing platforms and related consumables for analyzing genetic variation and biological function. Its instruments range from high-throughput NovaSeq systems to benchtop MiSeq/iSeq units, all built on sequencing-by-synthesis technology acquired from Solexa. Revenue comes from instrument sales plus a recurring stream of consumables, reagents, library preparation kits, and services. The company differentiates itself with a broad end-to-end ecosystem and strategic acquisitions (Solexa, GRAIL, SomaLogic) that expand capabilities into multiomics and clinical diagnostics.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1998

Get referred to Illumina

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Illumina raised 2026 revenue guidance to $4.60 billion-$4.64 billion after Q2 strength.
  • S&P 500 inclusion on September 21, 2026 should drive passive-fund buying.
  • Clinical volume reached 78% NovaSeq X conversion, supporting recurring consumables growth.

What critics are saying

  • FTC and Fifth Circuit GRAIL litigation still threatens forced divestiture and management distraction.
  • Research consumables declined in 2026 while clinical demand carried growth, exposing narrow dependence.
  • BGI and Thermo Fisher keep pressuring sequencing pricing, risking margin compression by 2027.

What makes Illumina unique

  • NovaSeq X drives clinical sequencing workflows, with 95 placements in Q2 2026.
  • Illumina pairs sequencing, DRAGEN software, and multiomics tools into one platform.
  • The new WGS MRD research solution broadens Illumina beyond core sequencing instruments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-2%
Yahoo Finance
Sep 9th, 2026
Illumina joins S&P 500 on 21 September following 112% stock surge

Illumina will join the S&P 500 index on 21 September, alongside Bloom Energy and Everpure, replacing Molson Coors Beverage, The Trade Desk, and Builders FirstSource. S&P Dow Jones Indices announced the rebalancing on Friday. The San Diego-based genetic sequencing company, valued at $33 billion, has returned 112% over the past 12 months. The inclusion will trigger buying from passive funds tracking the index. Illumina is moving from the S&P MidCap 400, signalling its growth into large-cap status. In the second quarter, the company reported revenue of $1.16 billion, up 9.5% year-over-year, with earnings per share rising approximately 10% to $1.31.

Yahoo Finance
Aug 26th, 2026
Illumina beats Q2 expectations with $1.16B revenue, raises full-year guidance

Illumina reported second-quarter revenues of $1.16 billion, marking a 9.4% year-on-year increase that exceeded analyst expectations by 2.5%. The DNA sequencing and microarray technology company delivered strong organic revenue performance and raised its full-year earnings guidance. Chief executive Jacob Thaysen attributed the results to growing momentum in sequencing-intensive applications among clinical customers. The company increased its revenue and earnings guidance for the year based on this performance. Illumina's shares rose 10% following the earnings announcement and currently trade at $225.55. The results came as part of a strong second quarter for the life sciences tools and services sector overall, with the 20 tracked stocks in the group beating revenue estimates by 2.6% on average.

GenomeWeb
Aug 14th, 2026
Illumina secures $1B credit facility with Bank of America, launches note offering

Illumina has entered into a $1 billion credit facility with Bank of America serving as administrative agent. The genomics company announced the agreement after market close on Thursday. The credit facility also includes an underwriting agreement for a note offering, though specific terms were not disclosed in the announcement.

AktienSensor
Aug 12th, 2026
Illumina raises $750M with 2029 senior notes to refinance debt and lower cost of capital

Illumina has filed to issue senior notes maturing in 2029, expecting to raise approximately $750 million. The unsecured notes will rank equally with the company's other unsecured debt and feature a yield near the current US Treasury benchmark. Proceeds will primarily repay an earlier 4.65% note due in September 2026. By extinguishing higher-cost debt, Illumina aims to reduce its interest burden and improve its debt-to-equity ratio. The company expects its weighted average cost of capital to decrease from 5.8% to an estimated 4.9%. The notes include a make-whole redemption clause and a change-of-control provision requiring Illumina to purchase notes at 101% of principal plus interest. Illumina holds Moody's A-3 and S&P A- credit ratings. The refinancing supports ongoing investment in next-generation sequencing platforms, data analytics, and cloud-based services whilst enhancing financial flexibility for strategic acquisitions and R&D funding.

PR Newswire
Jul 30th, 2026
Illumina raises 2026 guidance on strong Q2 results: $1.16B revenue, up 9.5%

Illumina reported second quarter 2026 revenue of $1.16 billion, up 9.5% from the prior year period. The San Diego-based genomics company posted GAAP diluted earnings per share of $1.35 and non-GAAP diluted earnings per share of $1.31. Chief executive Jacob Thaysen said momentum built through the first half of 2026 as the company's technology enabled clinical customers to expand sequencing-intensive applications. He noted that demand for NovaSeq X remains high. Based on this performance, Illumina raised its full-year 2026 revenue guidance to $4.60-$4.64 billion, up from prior guidance of $4.52-$4.62 billion. The company increased its non-GAAP diluted earnings per share guidance to $5.30-$5.40, versus prior guidance of $5.15-$5.30.